GMAC Board Election Affirms Continuity, Drive toward Business for Good

Bon Secours Mercy Health and Philips sign multi-year strategic collaboration

G7: MERMEC urges EU to prioritise the ERTMS railway signalling system

Pacific Green Achieves Planning Consent for its Limestone Coast, South Australia, 1.5GWh Battery Energy Parks

Andan Foundation Announces Award for Innovation in Refugee Inclusion in Collaboration with the Massachusetts Institute of Technology’s MIT Solve

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis

Notified -

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis

Accruent Sets New Standard in Workplace Space Optimization with Launch of Accruent Space Intelligence™

Marex Opens New Zealand Office

Acronis True Image Returns: Reintroducing Acronis' Trusted Home and Office Cyber Protection Solution

MGA Entertainment and Zapf Creation AG Complete Merger Forming MGA Zapf Creation GmbH

Bedford Metals Identifies Key Uranium Markers at Close Lake Uranium Project